Letko, Brosseau & Associates’s Aura Biosciences AURA Stock Holding History

Letko, Brosseau & Associates’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$189K	Hold	28,300	–	–	﹤0.01%	93
2025 Q4	$154K	Hold	28,300	–	–	﹤0.01%	93
2025 Q3	$175K	Buy	28,300 +7,100	+33%	+$46.4K	﹤0.01%	91
2025 Q2	$133K	Hold	21,200	–	–	﹤0.01%	89
2025 Q1	$124K	Hold	21,200	–	–	﹤0.01%	83
2024 Q4	$174K	Hold	21,200	–	–	﹤0.01%	94
2024 Q3	$189K	Hold	21,200	–	–	﹤0.01%	95
2024 Q2	$160K	Hold	21,200	–	–	﹤0.01%	98
2024 Q1	$166K	Buy	+21,200	New	+$176K	﹤0.01%	96

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Letko, Brosseau & Associates's AURA Position: Q1 2026 in Review

Letko, Brosseau & Associates held its Aura Biosciences (AURA) position steady in Q1 2026 at 28,300 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #93.

Letko, Brosseau & Associates first reported a position in AURA in Q1 2024 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

Letko, Brosseau & Associates held 28,300 shares of Aura Biosciences worth $189K as of Q1 2026.
Letko, Brosseau & Associates left its Aura Biosciences share count unchanged in Q1 2026.
Aura Biosciences made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #93 holding.
Letko, Brosseau & Associates first reported a position in Aura Biosciences in Q1 2024 and has held it in 9 quarters since.
126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.